Back to Search Start Over

Synthesis and characterization of silk fibroin microparticles for intra-articular drug delivery.

Authors :
Mwangi, Timothy K.
Bowles, Robby D.
Tainter, David M.
Bell, Richard D.
Kaplan, David L.
Setton, Lori A.
Source :
International Journal of Pharmaceutics. May2015, Vol. 485 Issue 1/2, p7-14. 8p.
Publication Year :
2015

Abstract

Objective To determine the utility of silk fibroin (SF) microparticles as sustained release vehicles for intra-articular delivery. Design SF formulations were varied to generate microparticle drug carriers that were characterized in vitro for their physical properties, release kinetics for a conjugated fluorophore (Cy7), and in vivo for intra-articular retention time using live-animal, fluorescence in vivo imaging. Results SF microparticle carriers were spherical in shape and ranged from 598 nm to 21.5 μm in diameter. SF microparticles provided for sustained release of Cy7 in vitro , with only 10% of the initial load released over 7 days. Upon intra-articular injection in rat knee joints, the SF microparticles were associated with an intra-articular fluorescence decay half-life of 43.3 h, greatly increasing the joint residence over that for an equivalent concentration of SF-Cy7 in solution form. The SF microparticles also increase the localization of dye within the joint cavity as determined by image analysis of fluorescent gradients, significantly reducing distribution of the Cy7 to neighboring tissue as compared to SF-Cy7 in free solution. Conclusion Silk microparticles act to provide for localized and sustained delivery of loaded small molecules following intra-articular injection, and may be an attractive strategy for delivering small molecule drugs for the treatment of arthritis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03785173
Volume :
485
Issue :
1/2
Database :
Academic Search Index
Journal :
International Journal of Pharmaceutics
Publication Type :
Academic Journal
Accession number :
101999904
Full Text :
https://doi.org/10.1016/j.ijpharm.2015.02.059